374 results about "Carcinoma Cell" patented technology

In alternative embodiments, provided are chimeric, synthetic or recombinant antibodies (Ab) against the human homologous box NKX-2. 1 (also known as NK2 homologous box 1, or thyroid transcription factor 1 (TTF-1)) protein, including articles of manufacture and kits comprising them, and methods of making and using them, including, for example, their use in the detection or diagnosis and treatment of cancer. In alternative embodiments, an anti-NKX-2. 1 (TTF-1) antibody provided herein is used with an agent for determining whether NKX-2. 1 (TTF-1) expression or activity is present, reduced or deleted; or the sensitivity of the specific binding of the Ab or the antigen (Ag) binding fragment or protein (ABP) or the monomer or dimer ABP provided by the invention with the squamous cell carcinoma cells is lower than the sensitivity of the specific binding with the adenocarcinoma cells (or binding with lower affinity), so that false positives of the squamous cell carcinoma are less, and the positive recognition of the lung adenocarcinoma is better.

The invention relates to the technical field of medical instruments, and provides a steep pulse-based ablation system and method for liver cancer cells, and the system comprises a tumor feature recognition module which is used for obtaining imaging images of the liver cancer cells and recognizing tumor features, blood supply conditions and tumor centers of the liver cancer cells; the electrode inlet setting module is used for setting a safety boundary of liver cancer cells and setting an ablation area and a focus skin surface of the liver cancer cells based on the safety boundary and tumor characteristics; the ablation effect analysis module is used for calculating the electrode depth and the electrode angle of the liver cancer cells and analyzing the coverage effect of an ablation area; the electric field intensity identification module is used for analyzing cell membrane characteristics of the hepatoma cells, identifying the electroporation effect of the hepatoma cells and identifying the electric field intensity of the hepatoma cells; and the steep pulse ablation module is used for performing ablation treatment on the liver cancer cells in combination with the electric field intensity and a pulse generator to obtain an ablation result. The invention aims to avoid heat injury of surrounding tissues and improve the ablation effect of liver cancer cells.

The invention discloses a limonin compound and application thereof in preparation of a medicine for preventing and / or treating cancers. The structure of the limonin compound is shown as a formula I or II. The cancer is at least one of breast cancer, liver cancer, gastric cancer, esophageal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, prostatic cancer, nasopharynx cancer, cervical cancer, ovarian cancer, kidney cancer and skin cancer. According to the invention, activity screening is carried out on various natural product extracts, it is found for the first time that limonin compounds with structural formulas I and II have excellent inhibitory activity on various different types of human cancer cells, and an optional scheme is provided for broad-spectrum anti-cancer drugs. Related results also show that the compound provided by the invention can inhibit migration and invasion ability of breast cancer cells, promote cell apoptosis and retard a cell cycle. The limonin compound applied in the invention is derived from mallotus oblongifolius, the source is wide, and the production cost is low.

The invention belongs to the technical field of biomedicine, and discloses an immortalized cell line for human kidney suspected cell carcinoma as well as a culture method and application of the immortalized cell line. The immortalized cell line for the human kidney suspected cell carcinoma, disclosed by the invention, is named as a human kidney suspected cell carcinoma cell line Loya a-710 (Homo sapiens), the classification name of the Latin name of the immortalized cell line is Chromophore sensor cell carcino: Loya a-710, and the preservation number of the immortalized cell line is CCTCC (China Center for Type Culture Collection) NO: C2025123. The human kidney suspected cell carcinoma cell line Loya-710 disclosed by the invention is used as an in-vitro model to rapidly grow in tissue culture, and mitochondrial mutation characteristics, a vesicle structure and a classical immunohistochemical marker of ChRCC are reserved. The invention provides a precious tool for further research on ChRCC heredity, molecules and biological characteristics, and also provides a powerful new model for mitochondrial diseases.

The invention relates to the technical field of biomedicine, in particular to a mouse intrahepatic bile duct cancer cell strain and a construction method and application thereof, the cell strain is named as mouse intrahepatic bile duct cancer cell strain KP-ICC and preserved in China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC NO: C202574; the cell strain is derived from a KrasG12D / Tp53flox / flox C57BL / 6J mouse, a spontaneous tumor model is constructed through high-pressure hydrodynamic tail vein injection of pT3-Cre and a sleep beauty transposase plasmid, and the spontaneous tumor model is obtained through in-vitro culture, passage, monoclonal screening and tumorigenicity verification. The KP-ICC cell strain naturally has chemotherapy-immune combined treatment drug resistance and ferroptosis resistance characteristics, and can be widely applied to the fields of intrahepatic cholangiocarcinoma drug resistance mechanism research, drug resistance reversing, combined treatment drug development, drug resistance animal model establishment and the like.

The invention discloses application of a composition containing isovaleric acid and lenvatinib in preparation of anti-cancer drugs, and belongs to the technical field of biological medicines. It is found for the first time that after the isovaleric acid and the lenvatinib are combined for use, the isovaleric acid and the lenvatinib have a synergistic effect, the anti-cancer activity of the composition containing the isovaleric acid and the lenvatinib can be remarkably improved, and especially the composition has better inhibitory activity on in-vitro liver cancer cells. Animal experiments further verify that the combination of isovaleric acid and lenvatinib can synergistically inhibit the growth of liver cancer cells in mice. Therefore, the composition containing the isovaleric acid and the lenvatinib has a relatively good application prospect in the prevention and / or treatment of the hepatocellular carcinoma.

The invention discloses a 5-substituted-3-(arylaminoethyl) benzoxazolone compound and a preparation method and application thereof.The compound takes CO2 as a carbonyl source, the preparation method is simple, raw materials are easy to obtain, and the compound has a good anti-cancer effect on the activity of cancer cells and particularly has a remarkable anti-cancer effect on the cancer cells such as HCCLM3 (human hepatoma carcinoma cells) and MCF-7 (human breast cancer cells).

The invention relates to application of recombinant humanized III-type collagen in preparation of an esophageal squamous cell carcinoma inhibitor. The invention discovers that the recombinant humanized III-type collagen can significantly inhibit the proliferation of esophageal squamous carcinoma cells and prevent the generation of malignant phenotypes of esophageal squamous carcinoma cells. Therefore, the invention can be used for preparing medicines for preventing and treating esophageal squamous carcinoma.

The invention belongs to the technical field of biological medicine, and provides CKS1B serving as an immunotherapy response prediction biomarker and application of the CKS1B, and according to the application, CKS1B serves as an immunotherapy response marker, and a CKS1B inhibitor is combined with an active component to treat a model mouse. In-vitro cell experiments are adopted to evaluate the immunotherapy prediction effect of the CKS1B as a biomarker on esophageal squamous carcinoma, a Cks1b overexpression tumor mouse model, a homologous mouse model and a human immune reconstruction mouse model are established, and a CKS1B inhibitor is combined with active ingredients to treat the two models; results show that the CKS1B inhibitor combined with the active component can promote removal of esophageal squamous carcinoma cells by CD8 + T cells, inhibit interferon signal channels and antigen presentation, effectively recover immune response, inhibit tumor cell proliferation and significantly reduce tumor volume, so as to achieve the purpose of treating esophageal squamous carcinoma.

The invention discloses an eccDNAcircATP6V0A1 serving as a predictive marker of cis-platinum drug resistance of hypopharyngeal cancer and an application of the eccDNAcircATP6V0A1. The nucleotide sequence of the predictive marker eccDNA is as shown in SEQ ID NO. 3. According to the invention, a hypopharyngeal carcinoma cisplatin drug-resistant cell line model FaDu / DDP is cultured for the first time, meanwhile, a differential eccDNA expression profile and a circRNA expression profile in hypopharyngeal carcinoma cells FaDu and hypopharyngeal carcinoma cisplatin drug-resistant cells FaDu / DDP are disclosed and analyzed in a combined manner, and the eccDNA circATP6V0A1 is further screened and verified as a predictive marker of hypopharyngeal carcinoma cisplatin drug resistance through combined analysis. And a new treatment strategy diagnosis and treatment thought is provided for cis-platinum chemotherapy of hypopharyngeal carcinoma patients clinically.

The present invention relates to lipid nanoparticle (LNP) compositions, as well as diagnostic or therapeutic polynucleotides, such as TERT mRNA, that can be delivered in a formulation together with the LNP compositions to various tissue and cell types in the whole body of a mammal, such as, for example, TNP mRNA. Comprising stem cells, progenitor cells, germ cells, differentiated cells or terminally differentiated cells, cancer cells, endothelial cells, epithelial cells, splenic cells, hepatocells, kidney cells and / or osteoblasts, for example, for use in the diagnosis, prevention and / or treatment of a condition or disease.

The invention relates to an application of Avasimibe in preparation of a medicine for treating nasopharynx cancer or oral cancer, and belongs to the field of tumor targeted therapy. An in-vitro cell experiment and an in-vivo animal model experiment verify the anti-tumor effect of the compound. Experiments show that Avasimibe can significantly inhibit the activity, proliferation ability, healing ability and cloning ability of nasopharynx cancer cells and oral cancer cells, can regulate cell cycle arrest in a dose-dependent manner, and induces cell apoptosis. In vivo experiments, the tumor volume of nude mice in an Avasimibe treatment group is remarkably reduced, serum cholesterol is remarkably reduced, and serum biochemical analysis shows that compared with a control group, the Avasimibe treatment group has no statistical difference in indexes such as aspartate transaminase (AST) / glutamic-pyruvic transaminase (ALT) and creatinine (Cr). The invention provides a new indication for resisting nasopharynx cancer and oral cancer for the existing compound Avassimibe, has the clinical advantages of low toxicity and capability of overcoming drug resistance, and provides a new treatment choice for patients with nasopharynx cancer and oral cancer.

The invention discloses a preparation method and application of lithospermum carbon nanodots with an anti-adrenal cortical carcinoma function, and relates to the field of carbon dots, the lithospermum carbon nanodots are prepared by the following steps: mixing a lithospermum extract and deionized water, and carrying out a hydrothermal reaction to obtain a lithospermum carbon dot aqueous solution; the lithospermum carbon nanodots are used for preparing medicines for resisting adrenal cortex cancer. The lithospermum carbon nanodot provided by the invention has an inhibition effect on proliferation of adrenal cortex cancer cells, especially on the adrenal cortex cancer cells ACHN and 769-P. The lithospermum carbon nanodot disclosed by the invention has a remarkable proliferation inhibition effect on ACC (adrenal cortical carcinoma) cells. The adrenal cortex cancer is a rare and malignant tumor, and traditional treatment methods such as surgery and chemotherapy have certain limitations. Therefore, the development of a new targeted therapy strategy is very important. The lithospermum carbon nanodots can effectively inhibit proliferation of adrenal cortex cancer cells such as ACHN and 769-P through a certain molecular mechanism.

The invention discloses an application of tripterine in preparation of an anti-esophageal cancer drug. The tripterine or the pharmaceutically acceptable salt thereof provided by the invention can be used for preparing medicines for preventing or treating esophageal cancer. The tripterine is adopted to achieve the effects of inhibiting proliferation of esophageal squamous carcinoma cells, inducing apoptosis of the esophageal squamous carcinoma cells, reducing the size of esophageal tumors and being small in side effect.

The invention belongs to the technical field of biological medicines, and discloses application of decitabine or an optical isomer thereof, or a hydrate thereof, or a solvate thereof, or a prodrug thereof, or a derivative thereof, or a pharmaceutically acceptable salt thereof in preparation of medicines for preventing and / or treating nasopharynx cancer. Or application in preparation of drugs for inhibiting postoperative recurrence and growth of nasopharyngeal carcinoma. In-vivo and in-vitro experiments prove that decitabine has the activity of remarkably inhibiting growth of nasopharyngeal carcinoma cells and is efficient and low in toxicity; the in-situ gel is prepared into the in-situ gel and is locally administrated through the nasopharyngeal cavity, so that toxic and side effects caused by a conventional treatment method can be avoided, tumor recurrence and growth can be remarkably inhibited after nasopharyngeal carcinoma operation, good safety is achieved, a new medicine and a new means are provided for prevention and treatment of nasopharyngeal carcinoma, and therefore the in-situ gel has wide application prospects.

The application discloses a dihydroquinazolinone-containing N-hydroxy amide compound and a preparation method and application thereof, relates to the technical field of medicinal chemistry, and utilizes the splicing principle to design and synthesize dihydroquinazolinone-containing N-hydroxy amide compounds with novel structures, and the compounds are tested in terms of HDAC6 protein affinity and anti-proliferation activity of cervical cancer cell Siha, and the results show that the compounds E1-E5 have better affinity to the HDAC6 protein, the IC 50 values are 4.1-85.4 nM, wherein the affinity of the compound E4 to the HDAC6 protein is higher than that of a positive control SAHA; and the compounds E1-E5 can better inhibit the proliferation of the cervical cancer cell Siha, the IC 50 values are 2.4-9.3 muM, wherein the activity of the compound E4 is the strongest.

The invention discloses an optical positioning method and system for papillary thyroid cancer cells of a terahertz near-field system, and relates to the field of terahertz near-field imaging, and the method comprises the following steps: carrying out the imaging observation of a thyroid tissue section under a first magnification factor through a microscope, carrying out low-magnification imaging partitioning on an area where imaging observation is located according to the morphological characteristics of the cells to form partitioned images; selecting an area of suspected papillary thyroid cancer cells, performing observation and comparison under a second magnification, comparing the observed morphology with the known optical characteristics of the papillary thyroid cancer cells, and selecting an area near the area with the suspected characteristics as an optical positioning point and performing marking; and carrying out positioning according to the optical positioning point, and carrying out scanning imaging by using a terahertz near-field system. The problems that a terahertz near-field system is long in time consumption and difficult to locate when finding papillary cancer cells in multiple cells of thyroid tissue slices are mainly solved.

The invention discloses a polypeptide and application thereof. The polypeptide TCL6148 is a polypeptide composed of an amino acid sequence as shown in SEQ ID NO: 1. The polypeptide TCL6148 is prepared by adopting a solid-phase synthesis method, it is proved for the first time that the polypeptide TCL6148 can inhibit proliferation and migration of renal cell carcinoma cells, and a new target spot and a new medication strategy are provided for treating renal cell carcinoma.

Proposed are antibodies specifically binding to PTK7 and a use thereof and, more particularly, PTK7 neutralizing antibodies specifically binding to PTK7 to inhibit PTK function, and a use thereof for inhibiting angiogenesis, cell growth, cell migration, and cell invasion. The human PTK7 neutralizing monoclonal antibodies have been found to independently exhibit an effective inhibitory effect on cancer cell growth, migration, invasion in esophageal squamous cell carcinoma and triple-negative breast cancer, and angiogenesis. Therefore, the human PTK7 neutralizing monoclonal antibodies can be applied to various PTK7-positive carcinomas and angiogenic diseases, and can be further developed as a targeted drug therapy for intractable cancers and angiogenic diseases to be used as a core global treatment drug for the same.

A human sebaceous gland carcinoma cell line and use thereof are provided. The human sebaceous gland carcinoma cell line SHNPH-SeC was deposited in the China Center for Type Culture Collection (CCTCC) on Aug. 31, 2023, with an accession number CCTCC NO: C2023113. The human sebaceous gland carcinoma cell line SHNPH-SeC carries a TP53 mutation, and has been identified as a novel single cell line by short tandem repeat (STR) genotyping. This human sebaceous gland carcinoma cell line exhibits strong adherence and stable cellular characteristics, can be stably passaged for multiple generations, and possesses rapid proliferation and migration capabilities, which are in line with the characteristics of malignant tumor cells.

The invention provides an application of ginkgetin in enhancing VS4718 or ponatinib in resisting the progress of esophageal squamous cell carcinoma. It is found that ginkgo biflavone can enhance the growth and invasion inhibition effect of VS4718 or ponatinib on esophageal squamous carcinoma cells; ginkgo biflavone is used for enhancing the inhibition effect of VS4718 or ponatinib on glycolipid metabolism of tumor cells, and the ginkgo biflavone is respectively combined with VS4718 or ponatinib to generate a synergistic anti-cancer effect.

The invention discloses a novel fusobacterium strain Fusobacteria sp.HPSCC05 and an application of the novel fusobacterium strain Fusobacteria sp.HPSCC05. The preservation number of the novel fusobacterium strain Fusobacteria sp.HPSCC05 is CCTCC (China Center For Type Culture Collection) NO: M2025588. According to the invention, Fusobacterium sp.HPSCC05 derived from hypopharyngeal squamous cell carcinoma tissues is successfully separated, the strain has key technical attributes of stable growth, repeatable culture, clear preservation conditions and the like, and the problem of deficiency of current hypopharyngeal carcinoma related strains is solved. Fusobacteria sp.HPSCC05 is identified as a new fusobacterium species, and the blank of hypopharyngeal carcinoma tumor ecological niche specific strain resources is filled up. The method comprises the following steps: establishing an in-vitro verification model (fusobacterium-hypopharyngeal squamous carcinoma cell co-culture model) of the hypopharyngeal carcinoma promoting effect of the Fusobacterium sp.HPSCC05, and providing a replicable culture mode;

The invention discloses application of PMF1 as a target spot in preparation of a product for diagnosing, preventing and / or treating hepatocellular carcinoma. According to the invention, the expression conditions of PMF1 in tumor tissues and normal liver tissues in hepatocellular carcinoma specimens are analyzed by using data of an on-line database, and it is found for the first time that the expression of PMF1 in hepatocellular carcinoma is up-regulated and the total survival rate of hepatocellular carcinoma patients with high PMF1 expression is low. Furthermore, experiments prove that the expression of the PMF1 in a hepatocellular carcinoma cell line is obviously higher than that of normal hepatocytes, proliferation, clone formation, migration and invasion of hepatocellular carcinoma cells can be effectively inhibited by reducing the expression level of the PMF1, and it is proved that interference on PMF1 gene expression can become a new way for preventing and / or treating hepatocellular carcinoma.

The invention relates to the technical field of biology, and particularly discloses application of LLPH as a lung cancer diagnosis biomarker and a treatment target spot, an LLPH expression inhibitor is an LLPH gene knockout plasmid and a genetic engineering construct containing sgRNA and a carrier, the LLPH expression inhibitor is suitable for CRISPR / Cas system mediated gene editing, the sgRNA sequence is 5 '-CTAAAGCTTACGGAGTAAG-3', the carrier is pX459M, and the enzyme cutting site is BbsI-BbsI; by detecting the relative expression quantity of LLPH in normal lung bronchial epithelial cells and lung cancer cell lines, it is found that LLPH is highly expressed in the lung cancer cell lines, and it is shown that LLPH is closely related to lung cancer development. The invention can provide a new biomarker for diagnosis of lung cancer. Lung cancer A549 and H1299 cells are used as models, and the LLPH gene is knocked out, so that the in-vitro malignant proliferation capacity of the lung cancer cells A549 and H1299 can be remarkably inhibited, and LLPH can be used as a potential treatment target for inhibiting lung cancer proliferation.

The present invention relates to a method of inducing mesenchymal-epithelial transition (MET) in a basal-like (or mesenchymal-like) cancer cell by contacting the cancer cell with an inducer of mesenchymal-epithelial transition for a time and under conditions sufficient to induce MET in the cell. Additionally, there is also provided a method of inhibiting epithelial-mesenchymal transition (EMT) of a cancer in a subject, the method comprising administering an inhibitor or regulator of lipid metabolism for a sufficient time and under conditions to inhibit epithelial mesenchymal transition (EMT) of the cancer in the subject.

The present invention belongs to the field of biomedical technology and discloses an immortalized cell line of human renal chromophobe carcinoma, a culture method and an application thereof. The immortalized cell line of human renal chromophobe carcinoma of the present invention is named human renal chromophobe carcinoma cell line Loya-710 (Homo sapiens), and its Latin name is Chromophobe renal cell carcinoma:Loya‑ 710 , deposited with CCTCC NO: C2025123. The human chromophobe renal cell carcinoma cell line Loya-710, as an in vitro model, grows rapidly in tissue culture and retains the mitochondrial mutations, vesicle structure, and classic immunohistochemical markers characteristic of ChRCC. This invention provides a valuable tool for further studying the genetic, molecular, and biological characteristics of ChRCC and offers a powerful new model for mitochondrial disease.

The invention discloses an application of an LAMP1 inhibitor in preparation of a medicine for preventing and / or treating esophageal cancer. Specifically, the application value of the LAMP1 inhibitor Parishin C in esophageal cancer treatment is found and verified for the first time, invasion and metastasis of esophageal squamous carcinoma cells and in-vivo lymph node metastasis can be remarkably inhibited by targeting LAMP1 protein and downstream signal channels of the LAMP1 protein and Parishin C, and a new drug choice is provided for metastatic esophageal cancer lacking effective treatment means clinically.

A system for evaluating the anticancer activity of a magnesium complex {[Mg(1,10-Phenanthroline)(H2O)4](1,3-Benzthiazol-2-thiolate) 2. 1,10-Phenanthroline} against oral squamous cell carcinoma, including: a cell culture apparatus configured to maintain human oral squamous cell carcinoma cells in a controlled environment with specific temperature and CO2 conditions; a compound delivery module configured to deliver predetermined concentrations of the magnesium complex to the cultured cells; a cell analysis unit configured to measure and analyze cellular responses to the magnesium complex; a flow cytometry device configured to analyze cellular parameters such as apoptosis and cell cycle progression; and a data processing unit configured to calculate and analyze cytotoxicity data and to generate inhibitory percentages.

The present invention belongs to the technical field of tumor molecular biology, and discloses an application of a reagent for inhibiting or detecting the expression of exosome miR-3150a-5p, as well as a drug for treating nasopharyngeal carcinoma metastasis and a prognostic preparation. The present invention found that the expression level of miR-3150a-5p in the serum exosomes of patients with nasopharyngeal carcinoma metastasis was significantly higher than that of patients without metastasis, and the area under the AUC curve was 0.84, the diagnostic sensitivity could reach 78%, and the specificity could reach 83%. It was confirmed that miR-3150a-5p has good application prospects in the prognosis of nasopharyngeal carcinoma patients. In addition, it was found that knocking down miR-3150a-5p significantly inhibited the expression of miR-3150a-5p in nasopharyngeal carcinoma cells and their secreted exosomes, and could effectively inhibit malignant progression such as nasopharyngeal carcinoma cell metastasis. This suggests the feasibility of using miRNA inhibitor to target and knock down miR-3150a-5p for the treatment of nasopharyngeal carcinoma.

The invention relates to the field of biological medicine, in particular to application of NPEPL1-targeted small molecule compounds in preparation of tumor targeted therapy drugs, and four small molecule compounds, namely C301-9181, E859-1332, L281-0443 and C679-2629, which have a hepatocellular carcinoma cell killing effect and high NPEPL1 affinity are obtained for the first time. The small molecule compound realizes tumor targeted therapy by targeting NPEPL1 protein in tumor cells, and can be used for developing tumor targeted therapy drugs. According to the present invention, the potential treatment effect of the targeted intervention NPEPL1 on hepatocellular carcinoma and other malignant solid tumors with high NPEPL1 expression is provided, the optimal small molecule compound C301-9181 is obtained through layer-by-layer screening, the small molecule compound can be used for preparing the NPEPL1-targeting anti-tumor targeting drugs, the drug research and development blank in the NPEPL1 targeting treatment field is filled, and the broad application prospect is provided.